Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALOX5 | P09917 | 4/20 | 0.36 |
| ▸ | MC4R | P32245 | 1/20 | 0.32 |
| ▸ | MC5R | P33032 | 1/20 | 0.32 |
| ▸ | MC3R | P41968 | 1/20 | 0.32 |
| ▸ | NOS2 | P35228 | 2/20 | 0.31 |
| ▸ | DPP4 | P27487 | 1/20 | 0.30 |
| ▸ | F2 | P00734 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9071877 | 0.80 | L3MBTL1 (0.41) | ALOX5 | |
| SCHEMBL8607828 | 0.79 | THRA (0.40) | — | |
| SCHEMBL1416138 | 0.79 | ALOX5 (0.42) | ALOX5 | |
| SCHEMBL6255211 | 0.77 | THRA (0.42) | — | |
| SCHEMBL30296278 | 0.77 | ALOX5 (0.41) | ALOX5 | |
| SCHEMBL21548898 | 0.77 | ALOX5 (0.41) | ALOX5MC4RMC5RMC3R | |
| SCHEMBL2497168 | 0.77 | ALOX5 (0.41) | ALOX5 | |
| SCHEMBL5262274 | 0.76 | ALOX5 (0.35) | ALOX5MC4RMC5RMC3RF2 | |
| SCHEMBL5264026 | 0.76 | ALOX5 (0.35) | ALOX5MC4RMC5RMC3RF2 | |
| SCHEMBL27971919 | 0.76 | ADH1A (0.47) | ALOX5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8158794-B2 | Hydroxyalkyl substituted imidazoquinoline compounds and methods | 3M INNOVATIVE PROPERTIES COMPANY (US) | 2012-04-17 | — | — | US | disclosed |
| US-20090069314-A1 | Hydroxyalkyl Substituted Imidazoquinoline Compounds and Methods | COLEY PHARMACEUTICAL GROUP, INC. (US) | 2009-03-12 | — | — | US | disclosed |
| EP-1851218-A2 | HYDROXYALKYL SUBSTITUTED IMIDAZOQUINOLINE COMPOUNDS AND METHODS | 3M Innovative Properties Company (US) | 2007-11-07 | — | — | EP | disclosed |
| WO-2006091567-A2 | HYDROXYALKYL SUBSTITUTED IMIDAZOQUINOLINE COMPOUNDS AND METHODS | COLEY PHARMACEUTICAL GROUP, INC. (US) | 2006-08-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090069314-A1 | Hydroxyalkyl Substituted Imidazoquinoline Compounds and Methods | IFNG, IRF3, IFNAR1 | ALOX5 762/4885MC4R 3151/4885MC5R 3680/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.